News|Articles|October 7, 2024
A Streamlined Platform Process to Accelerate Biotherapeutics from Gene to Clinic
Author(s)Catalent
Harmonizing technological innovation and a platform approach in biomanufacturing can reduce time and cost barriers to produce stable, high-expressing antibody-based therapeutics.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
2
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
3
Implementing Automation and Flexible Design for Allogeneic Manufacturing
4
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
5
